E
GOSS icon

Ergoteles’s Gossamer Bio GOSS Stock Holding History

Ergoteles’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-270
Closed -$25.9K – 375
2023
Q2 		$25.9K Sell
270
-21,379
-99% -$2.13M ﹤0.01% 978
2023
Q1 		$2.18M Buy
+21,649
New +$3.32M 0.09% 249
2022
Q1 		– Sell
-504
Closed -$456K – 1378
2021
Q4 		$456K Sell
504
-25
-5% -$23.8K 0.02% 679
2021
Q3 		$532K Buy
+529
New +$390K 0.02% 553

Other funds holding GOSS

NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EcoR1 Capital
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Octagon Capital Advisors
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Palo Alto Investors
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Boxer Capital
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Ergoteles's GOSS Position: Q3 2023 in Review

Ergoteles sold out of Gossamer Bio (GOSS) in Q3 2023, closing a stake of 270 shares — an estimated $25.9K sold.

Ergoteles first reported a position in GOSS in Q3 2021 and held it in 4 quarters. The position peaked at $2.18M in Q1 2023. 94 funds tracked by Wall St. Rank hold GOSS as of Q3 2023.

  • Ergoteles reported no remaining Gossamer Bio position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 270 Gossamer Bio shares in Q3 2023, an estimated $25.9K.
  • Ergoteles first reported a position in Gossamer Bio in Q3 2021 and held it in 4 quarters.
  • Ergoteles's Gossamer Bio position peaked at $2.18M in Q1 2023.
  • 94 funds tracked by Wall St. Rank held Gossamer Bio as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.